Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer

Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer

(2016) Justinas Besusparis et al.   Diagnostic Pathology

18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials

(2016) David Groheux et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

(2015) O. Humbert et al.   CLINICAL CANCER RESEARCH

18F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen

(2015) D. Groheux et al.   JOURNAL OF NUCLEAR MEDICINE

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer

(2014) David Groheux et al.   EUROPEAN JOURNAL OF CANCER

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial

(2013) C. Denkert et al.   ANNALS OF ONCOLOGY

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

(2013) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil–epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy

(2013) S. Ohno et al.   BREAST CANCER RESEARCH AND TREATMENT

Sequential 18F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy

(2013) Bas B. Koolen et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients

(2012) F. Bertucci et al.   ANNALS OF ONCOLOGY

Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis

(2012) Michail Ignatiadis et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer

(2012) D. Groheux et al.   JNCI-Journal of the National Cancer Institute

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis

(2011) Yuting Wang et al.   BREAST CANCER RESEARCH AND TREATMENT

Visualizing and assessing discrimination in the logistic regression model

(2010) Patrick Royston et al.   STATISTICS IN MEDICINE

Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues

(2009) Jérôme Toussaint et al.   BMC GENOMICS

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

(2009) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY